Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy (PAP_OXT)

This observational pilot study (n=10) will examine salivary oxytocin levels during a single dose of LSD as part of psychedelic-assisted psychotherapy (PAP) for anxiety disorders or depression.

The study, conducted by Geneva University Hospitals in Switzerland, aims to gather preliminary data on the reactivity of salivary oxytocin during LSD-assisted therapy. Participants will be selected from patients in the Addiction Department who have received approval for compassionate treatment with LSD for refractory anxiety or depression. On the day of their LSD treatment, participants will provide four saliva samples to measure oxytocin levels, in addition to completing standard self-report questionnaires.

The researchers will not interfere with the usual clinical routine, but will collect these additional biomarker measurements. This pilot study could provide valuable insights into the physiological mechanisms underlying the therapeutic effects of psychedelic-assisted psychotherapy, potentially identifying salivary oxytocin as a relevant biomarker for future research in this field.

Topic Depression Anxiety
Compound LSD
Country Switzerland
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University Hospital Geneva
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.